Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 28,000 shares at $121.59 ($3.4M) on 2024-05-08, disclosed to the SEC on 2024-05-10.
Scheduled sale ($3.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $120.37 | 2,000 | $241K | 7.1% |
| 2 | $121.59 | 5,004 | $608K | 17.8% |
| 3 | $121.59 | 5,004 | $608K | 17.8% |
| 4 | $122.07 | 7,996 | $976K | 28.6% |
| 5 | $122.07 | 7,996 | $976K | 28.6% |
| Total | $121.78 avg | 28,000 |
| $3.4M |
| 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |